Loading KRYS detail
Loading ticker data...
Loading KRYS detail
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.
Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product.
Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Chart data unavailable
Krystal Biotech has attractive prospects within its core market. The biotech could launch more products in the next few years.
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech position increased by $50.33 million, reflecting both trading and price movement effects.
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) shares gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $276.45, but opened at $289.00. Krystal Biotech shares last traded at $285.45, with a volume of 212,409 shares. The company reported $1.70 earnings per
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajectory, high gross margins (94%), and disciplined R&D and SG&A spending. Phase 1 KB407 data in cystic fibrosis confirms molecular proof-of-concept, with a $2B+ opportunity targeting modulator-ineligible and suboptimal responder patients.
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S.
Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.
Cookson Peirce and Co. Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,654 shares of the company's stock, valued at approximately $998,000. A number of other institutional investors have also added
Alps Advisors Inc. cut its stake in Krystal Biotech, Inc. (NASDAQ: KRYS) by 23.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,367 shares of the company's stock after selling 4,095 shares during the period. Alps Advisors Inc.'s
Krystal Biotech maintains a 'Strong Buy' rating, driven by robust VYJUVEK sales and significant pipeline progress. Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated patients. A single registrational trial of KB707 plus chemotherapy versus chemotherapy alone may support regulatory filing, with interim analysis expected in H2 2026.
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.
Principal Financial Group Inc. raised its position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) by 1.4% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 142,843 shares of the company's stock after buying an additional 1,960 shares during the quarter. Principal Financial
